Download full-text PDF

Source
http://dx.doi.org/10.1097/00002030-199904160-00016DOI Listing

Publication Analysis

Top Keywords

reappearance hiv
4
hiv antibody
4
antibody infected
4
infected seronegative
4
seronegative individual
4
individual treatment
4
treatment highly
4
highly active
4
active antiretroviral
4
antiretroviral therapy
4

Similar Publications

Undiagnosed AIDS in a 13-year-old boy in rural Gabon.

IDCases

October 2024

Center for Tropical Medicine, Bernhard-Nocht Institute for Tropical Medicine & I. Dept. of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Article Synopsis
  • Prevalence of HIV
  • : Approximately 38.4 million people live with HIV globally, with a significant number (1.7 million) being children under 14, primarily in sub-Saharan Africa, where mother-to-child transmission is common and diagnoses are often delayed.
  • Case Report
  • : A 13-year-old boy from rural Gabon experienced repeated fever and fatigue for years, leading to multiple undiagnosed hospital visits. Ultimately, he was diagnosed with late-onset AIDS after serologic testing revealed HIV-1 infection.
  • Importance of Early Detection
  • : The case underlines the critical need for HIV testing in children and adolescents, especially in malaria-prone areas, as early diagnosis can significantly improve
View Article and Find Full Text PDF

Organic compounds can crystallize in different forms known as polymorphs. Discovery and control of polymorphism is crucial to the pharmaceutical industry since different polymorphs can have significantly different physical properties which impacts their utilization in drug delivery. Certain polymorphs have been reported to 'disappear' from the physical world, irreversibly converting to new ones.

View Article and Find Full Text PDF

HIV rapidly rebounds after interruption of antiretroviral therapy (ART). HIV-specific CD8+ T cells may act to prevent early events in viral reactivation. However, the presence of viral immune escape mutations may limit the effect of CD8+ T cells on viral rebound.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the long-term safety and effectiveness of withdrawing hepatitis B immunoglobulins (HBIg) in patients who underwent liver transplantation for hepatitis Delta and hepatitis B-related cirrhosis.
  • A cohort of 16 patients who discontinued HBIg after a median of 24.5 months showed no recurrence of HDV/HBV infections during a follow-up period of over 11 years, with half developing immunity to HBV.
  • The findings suggest that HBIg withdrawal is a viable strategy post-transplant and may warrant a reevaluation of existing prophylactic treatment guidelines for these patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!